Jan Wald
![Jan Wald](/assets/img/authors/unknown.jpg)
Jan Wald
acid might passed test
They might have passed the acid test of being too big.
beginning fourth looked looking quarter
The end of the fourth quarter looked better than the beginning, and 2006 is looking OK.
feeling
I have a feeling that Temecula is pretty safe.
hard people work
People are Guidant's most important asset, ... so there are hard trade-offs for Guidant to work through.
attractive certainly definitely
I think they (St. Jude) definitely look like they are in play. They certainly would be an attractive candidate.
actions company eventually expenses given remain stay
I think there are some actions the company will have to take and some expenses the company will have to incur that will make it tough. I still think given those parameters, it can be, stay and remain an independent company and eventually flourish.
certainly company
I certainly think it could be a stand-alone company. I'm not certain it should be.
closing concerned delay interest though
Integration is going full-speed ahead. I don't think they would be concerned by a two-week delay in closing the deal, even though there's an interest payment.
boston deal power reach scientific
Boston Scientific will do everything in its power to reach a deal with Guidant.
among employees
There's a lot of frustration among institutional shareholders and employees who own the stock.
along believe boston deal matter small strategic
I don't believe these things are going to matter for Boston Scientific. This is a strategic deal for them and these are small perturbations along the way.
boston less time worse
The less time they give Boston Scientific, the worse it is for Boston Scientific. They have less time to react.
growth jude needs people thinking walk
J&J needs something like Guidant to revitalize its growth. People are now thinking that if J&J does walk away, St. Jude is in their scopes.
accept board boston clearing price scientific terms
The price wasn't as important as clearing up some terms and conditions. If Boston Scientific has done that, then I don't know why Guidant's board wouldn't accept this bid.